Dr. Crawford talks about a new epigenetic test that helps to prevent unnecessary biopsies in men with prostate cancer.
A new study shows that exercise may reduce the risk of developing prostate cancer in Caucasian men, but not African Americans.
Significant associations seen in men's urinary and sexual function based on surgeon.
This week, the FDA approved radium-223 injection for the treatment of CRPC with symptomatic bone metastases.
Researchers say they have identified genetic variants that can increase PSA concentrations and prostate cancer risk.
Radium-223, a first-in-class drug, travels directly to the site of bone metastases, where it emits alpha particles that exert an anti-tumor effect.
Researchers studied 850 testosterone-deficient men who received 1,000 mg parenteral testosterone undecanoate six weeks after baseline and then every 12 weeks for up to five years.
A large, international trial has found intermittent ADT is not equivalent to continuous ADT.
Shared decision-making about screening recommended for men aged 55-69 years.
Median survival time from diagnosis improved by a median of 43 months from the pre-PSA to the post-PSA era.
In fact, men on testosterone replacement therapy (TRT) had a lower PCa rate than men not on TRT.
Data support prophylactic use of a PDE-5 inhibitor in men receiving radiotherapy for prostate cancer.
This approach can reduce adverse events without impairing efficacy.
Study finds a significant inverse association between weight changes and incontinence scores in normal-weight patients.
New findings underscore the importance of achieve maximal tumor control in patients with high-risk disease.
Patients with pT4 tumors had five-year cancer-specific and overall survival rates of 91%.
After more than 10 years of follow-up, 54% of patients progressed, but only one patient died from prostate cancer.
Compared with negative margins, they are associated with a 51% increased risk of biochemical relapse
Study reveals an elevated risk of lung cancer, which researchers called an intriguing finding.
The incidence is 10 times greater for men with rheumatoid arthritis compared with the general population.
Following surgery, symptom severity declined significantly and remained stable over 10 years.
Pathologic progression not more likely in patients who start active surveillance with a PSA of 10 ng/mL or higher, study finds.
They are more likely than non-blacks to experience progression and to abandon active surveillance.
Rate rose from 38.2% in 2005 to 42.5% in 2011.
Only 22% of randomized clinical trials reported participation of black men.
Older men with non-metastatic PCa and who have multiple major comorbidities are at high risk of dying from other causes.
Study of PCa patients who had equal access to healthcare found that those most likely to die from it had metastatic disease at presentation.
Study reveals cancer-specific and metastasis-free survival rates of 97% and 94% with high-intensity focused ultrasound.
A new study suggests that male carriers of the gene mutation are at greater risk of having advanced prostate cancer at the time of diagnosis.
For postmenopausal women, sclerostin up within two days; returns near to baseline after 360 days.